Nanomedicinal delivery approaches for therapeutic siRNA.
RNA interference (RNAi) has been named as "breakthrough technology" in 2002 by Science magazine. In a short timespan this technology has conquered life sciences and numerous therapeutic approaches and is now well underway to become an important pilier of novel class of RNA based therapeutics. This mini-review focuses on nanomedicinal delivery approaches for siRNA that have shown promise with small molecules, and have recently been applied with the aim to deliver siRNA to humans for treatment of disease.
Keller
Michael
M
Novartis Pharma AG, Technical R&D, CH-4057 Basel, Switzerland. michael-1.keller@novartis.com
D000818:Animals; D018014:Gene Transfer Techniques / Q000639:trends; D015316:Genetic Therapy / Q000379:methods / Q000639:trends*; D006801:Humans; D050997:Nanomedicine / Q000379:methods / Q000639:trends*; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000235:genetics
D034741:RNA, Small Interfering